Welcome to our dedicated page for Quantum-Si news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si stock.
Quantum-Si Incorporated develops proteomics technology for single-molecule protein sequencing and protein analysis. Its updates center on benchtop platform development, real-time kinetic-based detection, and product work around Proteus instruments, the KinetIQ Array and Platinum Pro customer use.
Recurring company news includes quarterly financial results and non-GAAP operating measures, Proteus prototype and integrated-instrument sequencing milestones, amino-acid detection coverage, customer sample testing, scientific posters and manuscripts using Quantum-Si technology, investor conference participation, and equity-inducement grants under Nasdaq rules.
Detect, Inc. announces that its PCR-quality at-home Covid-19 Test has received Emergency Use Authorization from the U.S. FDA. The test provides results in one hour, making it ideal for home, school, and workplace use. With an overall agreement of 97.3%, a sensitivity of 90.9%, and 100% specificity, it is among the most accurate home tests available. Priced under $50, it stands as the lowest-cost molecular test on the market. The test is designed to detect all current variants of concern and is supported by an $8.1 million NIH contract to scale up manufacturing.
Quantum-Si (NASDAQ:QSI) will report its Q3 2021 financial results on November 11, 2021, before market open. CEO John Stark and CFO Claudia Drayton will host a conference call at 8:30 a.m. ET on the same day to discuss the financial results and provide a business update. The call will be accessible via webcast and by phone.
Quantum-Si (NASDAQ: QSI) has expanded its Platinum early access program to ten global sites, including notable academic centers and industry partners. This initiative aims to enhance understanding of the proteome, which currently sees only 2% of its estimated million protein structures analyzed. The program supports the development of multi-omic assays and advanced biomarker characterization, positioning Quantum-Si to address critical biological research needs. CEO John Stark emphasizes the company's momentum in transforming proteomics and advancing drug discovery.
Detect, Inc. has secured an $8.1 million funding award from the National Institutes of Health (NIH) under the RADx initiative to advance its Detect™ Covid-19 Test. This test is currently pending FDA Emergency Use Authorization and promises PCR-quality results at home in approximately one hour. The funding will aid in scaling manufacturing to meet national demand. Designed for schools, businesses, and homes, the Detect Covid-19 Test targets all known Covid-19 variants, including Delta, enhancing accessible testing options in the U.S.
Quantum-Si Incorporated (NASDAQ: QSI) announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30, 2021. CEO John Stark and CFO Claudia Drayton will host a virtual fireside chat on September 29 from 1:20 to 1:50 PM EDT. Quantum-Si is focused on advancing proteomics through a novel semiconductor chip enabling next-generation protein sequencing. For more details, visit the Investor Relations section on their website.
Founded in 2013 by Dr. Jonathan Rothberg, Quantum-Si aims to transform drug discovery and diagnostics.
Quantum-Si (Nasdaq: QSI) announced its second-quarter 2021 financial results, highlighting a net loss of $35.7 million, up from a loss of $8.2 million in Q2 2020. Operating expenses surged to $32.2 million, a 292% increase year-over-year. Positive developments included the completion of a business combination with HighCape, adding over $511 million in cash, and the delivery of five early access systems to key thought leaders in the proteomics field. The company plans to build a 25,000 square foot facility in San Diego to enhance R&D and production capabilities.
Quantum-Si announced the rescheduling of its second quarter 2021 financial results conference call to August 16, 2021, post-market close. CEO John Stark and CFO Claudia Drayton will host the call at 4:30 p.m. ET to discuss financial results and a business update. The call will be available via webcast on the Investor Relations website. Quantum-Si, founded in 2013, focuses on semiconductor chip-based proteomics, leveraging technology aimed at advancing drug discovery and diagnostics beyond DNA sequencing.
Quantum-Si Incorporated plans to report its second quarter 2021 financial results on August 12, 2021, prior to market opening. CEO John Stark and CFO Claudia Drayton will hold a conference call at 8:30 a.m. ET on the same day to discuss the results and provide a business update. The call can be accessed via a live webcast on the company's Investor Relations website. Quantum-Si is focused on advancing proteomics through innovative semiconductor technology for protein sequencing.
Quantum-Si Incorporated has signed a lease with Phase 3 Real Estate Partners for a 25,586-square-foot facility in San Diego, CA. This site will enhance its product development and R&D capabilities, crucial for recruiting talent and commercial readiness in the proteomics market. Operations are anticipated to commence in Q3 2021. CEO John Stark emphasized the facility's role in scaling operations to meet the growing demand for protein sequencing technologies, which are expected to revolutionize drug discovery and diagnostics.
Quantum-Si Incorporated (Nasdaq: QSI) has successfully completed its business combination with HighCape Capital Acquisition Corp. (Nasdaq: CAPA), resulting in over $500 million for the development of its semiconductor chip-based protein sequencing technology. The combined company, now trading as Quantum-Si, aims to disrupt the $21 billion academic research and drug discovery market with its unique end-to-end solution. The company’s leadership includes experienced executives and it anticipates launching its products commercially in 2022.